Jiangsu Genloci Biotechnologies

Jiangsu Genloci Biotechnologies (also known as Jirui Biology) is a high-tech biotechnology company founded in 2011 by Dr. Jianqun Ling. Headquartered in Nanjing, China, the company focuses on the research, development, manufacturing, and sales of innovative peptide therapeutics, antibodies, and gene therapies. Genloci has established four core technology platforms: the proprietary IOS gene editing platform, a comprehensive peptide drug platform, a CHO-SC cell line and CHO-MCI site-specific integration platform for antibody development, and an ultra-low-cost vaccine production platform. Its clinical pipeline includes GB002, a recombinant peptide inhalation solution in Phase 2 clinical trials for hospital-acquired pneumonia, and GB001, a recombinant peptide spray in Phase 2 trials for wound healing and anti-inflammation. Additionally, the company produces and sells cell culture contamination control reagents, peptide raw materials, and antibacterial products under the Fem (芬母) brand.